Compare SYM & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYM | HALO |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 8.1B |
| IPO Year | 2021 | 2001 |
| Metric | SYM | HALO |
|---|---|---|
| Price | $41.14 | $68.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | $62.50 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 2.5M | 1.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.03 | ★ 1.22 |
| Revenue | ★ $2,246,922,000.00 | $151,862,000.00 |
| Revenue This Year | $24.75 | $28.24 |
| Revenue Next Year | $27.90 | $12.56 |
| P/E Ratio | $1,381.00 | ★ $55.63 |
| Revenue Growth | ★ 25.65 | N/A |
| 52 Week Low | $37.45 | $51.06 |
| 52 Week High | $87.88 | $82.22 |
| Indicator | SYM | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 37.27 | 48.43 |
| Support Level | N/A | $66.31 |
| Resistance Level | $57.22 | $70.54 |
| Average True Range (ATR) | 2.42 | 2.34 |
| MACD | -0.23 | -0.25 |
| Stochastic Oscillator | 21.09 | 44.14 |
Symbotic Inc. is an automation technology company that develops solutions to improve operating efficiencies in modern warehouses. The group designs, commercializes, and deploys end-to-end technology systems that significantly enhance supply chain operations. The company automates the processing of pallets, cases, and individual items within warehouse environments. Its systems strengthen operations at the front end of the supply chain and provide benefits to all supply partners downstream. The company operates in two geographical regions: the United States and international markets, with the majority of its revenue generated in the United States.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.